NASDAQ OMX

Global Survey Released by ISAPS Reports Increase of Over One Million Cosmetic and Aesthetic Procedures Performed in 2015

Del

NEW YORK, 2016-07-26 10:00 CEST (GLOBE NEWSWIRE) -- The worldwide reach of the International Society of Aesthetic Plastic Surgery (ISAPS) is well known to the global plastic and aesthetic surgery community.  Now the release of eagerly awaited procedural survey results shows an increase of over one million reported procedures from 2014 to 2015.

The data on surgical and non-surgical treatments performed in 2015 was tabulated from a questionnaire sent to approximately 35,000 plastic surgeons in the proprietary ISAPS database. ISAPS is the only organization that collects this type of data on a global scale and the study is viewed as a valuable resource in the field of aesthetics.

Of course the most awaited features of the survey are the most popular types of procedures in the world by country. Botulinum Toxin (BOTOX®) continues to reign supreme for both men and women with a total of over 4.6 million procedures reported.  Another popular injectable, Hyaluronic Acid, increased 6.5% from 2014 to 2015.  Breast augmentation continues to be the most common surgical procedure among women with a 10.4% increase from 2014 while eyelid surgery is prevalent among men.  

Most Popular Surgical Procedures in 2015:

Procedure 2015 2014 Percentage
Breast Augmentation 1,488,992 1,348,197   10.4 %
Liposuction 1,394,588 1,372,901   1.6 %
Eyelid Surgery 1,264,702 1,427,451   -11.4 %
Abdominoplasty 758,590 682,568   11.1 %
           

Most Popular Non-Surgical Procedures in 2015:

Procedure 2015 2014 Percentage
Botox 4,627,752 4,830,911   -4.2 %
Hyaluronic Acid 2,865,086 2,690,633   6.5 %
Hair Removal 1,099,053 1,277,581   -14.0 %
Photo Rejuvenation 568,672 -   -  
Non-Surgical Fat Reduction  425,315 -   -  
           

“We are proud to share these survey results to show the growing momentum in highly practiced areas,” noted Susumu Takayanagi, MD, ISAPS president. “ISAPS’ membership includes thousands of top plastic surgeons who take time to contribute to these findings,” he states.   The results can be accessed on the ISAPS website http://www.isaps.org in the News section, and will be discussed during the 23rd ISAPS biennial global conference in Kyoto, Japan, October 23-27, 2016.

The country with the highest number of procedures is the United States with 1.4 million surgical and 2.6 million non-surgical procedures.  Brazil reported 1.2 million surgical and 1.1 million non-surgical procedures.  Rounding out the list for the most procedures are South Korea, India, Mexico, Germany, Colombia, France, and Italy. 

The United States has the largest number of active plastic surgeons with 6,500 followed by Brazil with 5,500 and China with 2,800.  Numbers by country are evidenced in the report; however, some countries did not provide required updates this year.

Women had more than 18 million surgical and non-surgical procedures performed globally, 85.6% of the total. The top five surgical procedures performed on women in 2015 were: breast augmentation, liposuction, eyelid surgery, abdominoplasty and rhinoplasty.

Men had more than 3 million surgical and non-surgical procedures, 14.4% of the total. The top five surgical procedures performed on men were: eyelid surgery, liposuction, gynecomastia surgery, rhinoplasty, fat grafting and ear surgery.

The International Survey on Aesthetic/Cosmetic Procedures Performed in 2015 was compiled, tabulated, and analyzed by Industry Insights, Inc. http://www.industryinsights.com, an independent research firm based in Columbus, OH.

About ISAPS:
The International Society of Aesthetic Plastic Surgery is the premier global organization for board certified (or the equivalent) plastic surgeons. Regarded as the leading global educator in aesthetic procedures, ISAPS offers its more than 3,200 members over 30 courses, workshops and symposia each year conducted by a world-class faculty with the primary goal of teaching aesthetic best practices and ensuring patient safety. Through its rigorous membership screening, ISAPS is a guardian of patient safety internationally, making it the patient's global resource to find qualified and experienced aesthetic plastic surgeons.

         Media Contact:
         Julie Guest, ISAPS Chief Marketing Officer
         Media@ISAPS.org
         1-844-867-3621

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

TEAM Industries Announces New Innovative Transmission Incorporating Fallbrook's NuVinci® CVP Technology24.10.2017 02:25Pressemelding

Design is ready for vehicle implementation in powered recreational and utility vehicles CEDAR PARK, TEXAS and BAGLEY, MINNESOTA, Oct. 23, 2017 (GLOBE NEWSWIRE) -- TEAM Industries (TEAM) and Fallbrook Technologies Inc. (Fallbrook) announced today that TEAM has a production-ready innovative new transmission design for all-terrain vehicles (ATV) and utility task vehicles (UTV) available to OEMs for vehicle implementation. The transmission incorporates Fallbrook's NuVinci® continuously variable planetary (CVP) technology. NuVinci is a platform technology for a new class of continuously variable transmissions (CVT). It utilizes spheres instead of gears or belts, and can be deployed in a wide variety of applications to improve performance and/or system efficiency. TEAM has an exclusive licensing agreement with Fallbrook for the use of NuVinci CVP technology in North America and Europe in electric and gasoline light vehicle applications. TEAM is also workin

Telix Pharmaceuticals and ANMI Partner for Prostate Cancer Imaging24.10.2017 01:00Pressemelding

MELBOURNE, Australia and LIÈGE, Belgium, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, Company), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR), is pleased to announce that it has entered into a development and commercialization partnership with Advanced Nuclear Medicine Ingredients SA (ANMI). Under the terms of the agreement, Telix and ANMI will partner to commercialise ANMI's 68Ga-HBED-CC-PSMA (68Ga-PSMA-11) kit (Kit), a proven technology used to accurately image and stage metastatic prostate cancer, in the US market. Telix will also offer the Kit on a worldwide basis as a companion diagnostic imaging agent to the Company's prostate cancer therapeutic (TLX-591)1. The agreement includes filing a Drug Master File (DMF) for the Kit, and completion of the necessary clinical trials to obtain marketing authorisatio

Telix Pharmaceuticals Limited Launches $50 Million Underwritten Initial Public Offering (ASX: TLX)23.10.2017 23:00Pressemelding

MELBOURNE, Australia, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, the Company), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), is pleased to announce the opening of its Initial Public Offering (IPO or Offer) to raise A$50 million. The IPO is an offer by Telix for the issue of 77.0 million shares at $0.65 per share and is fully underwritten by the Lead Managers, Taylor Collison Limited and Wilsons Corporate Finance Limited. The IPO has been strongly supported by the Company's existing shareholders, which include both industry partners and domestic institutional investors, such as Acorn Capital, CVC, Monash Investors, Viburnum Funds, Allan Moss and Alium Capital Management. With this Offer, Telix will further strengthen its Australian and international institutional shareholder base, including the addition of Fidel

Brookfield Asset Management Notice of 2017 Q3 Results Conference Call and Webcast23.10.2017 17:03Pressemelding

Date:    Thursday, November 9, 2017 Time:   11:00 a.m. (Eastern Time)  BROOKFIELD, News, Oct. 23, 2017 (GLOBE NEWSWIRE) -- You are invited to participate in Brookfield Asset Management's 2017 Third Quarter Conference Call & Webcast on Thursday, November 9, 2017 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on November 9th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com "News - Press Releases." The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial 1-800-319-4610 toll free in North America, or for overseas calls please dial 1-604-638-5340 at approximately 10:50 a.m. The Conference Call will also be Webcast live at http://servic

Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines23.10.2017 13:00Pressemelding

LOWELL, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the receipt of a $7.3 million contract from the Biomedical Advanced Research and Development Authority (BARDA) for the implementation of a rapid sterility test for vaccines. This awarded grant is part of BARDA's Advance Development of Medical Countermeasures for Pandemic Influenza, which focuses on improving the government's responsiveness to future pandemic threats. When combined with Rapid Micro Biosystems' automated Growth Direct(TM) detection system, the rapid sterility test will result in faster release of vaccines and other sterile products. Timely delivery of these products carries multiple public benefits, principally in facilitating rapid responses to pandemic or emerging infections, agents of bioterrorism, and availability of life saving medicines. "Our continuing relationship with BARDA demonstrate

Xehar Fashion App Ditches the Shopping Cart and Picks Up Speed23.10.2017 12:00Pressemelding

New fast fashion app will shorten the checkout time by removing the shopping cart altogether. PLAYA VISTA, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Fashion tech company Xehar, today announces they will be removing the shopping cart from their Xehar shopping app. For millennial women shoppers who are interested in fashion but are frustrated with the online shopping experience, the Xehar app is their solution. "Xehar has found a way to increase conversion for app purchases by simply removing the function of the shopping cart," says Hadari Oshri, founder and CEO of Xehar. "Within the app, users select complete outfits and purchase with ease. By removing the shopping cart we are reducing friction and speeding up the checkout process." A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c58ce496-70e7-4675-8f59-3e39725708c4 Website and app owners deal with the reality of shopping cart abandonment

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom